CardioCell LLC has just received the FDA's investigational new drug approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure , which generates more than 1 million hospitalizations annually.
http://ift.tt/1fsC0OD
http://ift.tt/1fsC0OD
No comments:
Post a Comment